We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+81.78%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$631M
AUM Growth
+$215M
Cap. Flow
+$89.7M
Cap. Flow %
14.22%
Top 10 Hldgs %
69.95%
Holding
56
New
19
Increased
12
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.2M
2
UGL icon
ProShares Ultra Gold
UGL
+$20.2M
3
ABVX
Abivax
ABVX
+$13.8M
4
SLNO
Soleno Therapeutics
SLNO
+$13.2M
5
QURE icon
uniQure
QURE
+$12M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$56.9M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3M
3
INSM icon
Insmed
INSM
+$2.51M
4
LLY icon
Eli Lilly
LLY
+$1.49M
5
SRRK icon
Scholar Rock
SRRK
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.2B
$105M 16.71%
732,212
-20,500
-3% -$2.51M
ARGX icon
2
argenx
ARGX
$57.4B
$57.8M 9.16%
78,311
– –
INSM icon
3
CALL
Insmed
INSM
$23.2B
$57.6M 9.13%
400,000
+360,000
+900% +$44.1M
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$45.4M 7.2%
672,176
+177,752
+36% +$13.2M
VRNA
5
DELISTED
Verona Pharma
VRNA
$40.4M 6.41%
379,004
-545,200
-59% -$56.9M
QURE icon
6
uniQure
QURE
$2.68B
$38.5M 6.1%
+658,839
New +$12M
MRUS
7
DELISTED
Merus
MRUS
$27.9M 4.43%
296,750
– –
UGL icon
8
ProShares Ultra Gold
UGL
$650M
$24.8M 3.92%
+537,372
New +$20.2M
LLY icon
9
Eli Lilly
LLY
$1.07T
$21.9M 3.47%
28,700
-2,000
-7% -$1.49M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$121B
$21.6M 3.42%
55,100
+50,700
+1,152% +$21.2M
ABVX
11
Abivax
ABVX
$11B
$19.1M 3.03%
+225,453
New +$13.8M
TRVI icon
12
Trevi Therapeutics
TRVI
$2.49B
$18.3M 2.9%
1,999,702
+687,862
+52% +$5.16M
BSX icon
13
Boston Scientific
BSX
$65.8B
$17.9M 2.84%
183,200
+28,000
+18% +$2.9M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$36.3B
$15.8M 2.5%
34,570
+13,600
+65% +$5.54M
DGX icon
15
Quest Diagnostics
DGX
$25.1B
$15.6M 2.47%
81,717
– –
AZN icon
16
AstraZeneca
AZN
$263B
$14.6M 2.32%
95,376
– –
EYPT icon
17
EyePoint Inc
EYPT
$1.02B
$8.95M 1.42%
628,367
+311,667
+98% +$3.59M
REGN icon
18
Regeneron Pharmaceuticals
REGN
$68.8B
$6M 0.95%
10,671
– –
NAMS icon
19
NewAmsterdam Pharma
NAMS
$3.47B
$5.54M 0.88%
194,838
+167,519
+613% +$4.02M
RVMD icon
20
Revolution Medicines
RVMD
$40.2B
$4.87M 0.77%
104,190
– –
RNAM
21
DELISTED
Avidity Biosciences
RNAM
$4.8M 0.76%
110,100
+75,500
+218% +$3.05M
RARE icon
22
CALL
Ultragenyx Pharmaceutical
RARE
$2.65B
$4.51M 0.72%
+150,000
New +$4.5M
DNTH icon
23
Dianthus Therapeutics
DNTH
$5.68B
$4.28M 0.68%
+108,723
New +$2.78M
IONS icon
24
Ionis Pharmaceuticals
IONS
$9.35B
$3.94M 0.62%
+60,176
New +$2.94M
VKTX icon
25
Viking Therapeutics
VKTX
$4.04B
$3.84M 0.61%
146,179
+49,700
+52% +$1.48M
1
2 3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Artia Global Partners held 56 positions worth $631M, up 52% from $416M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Artia Global Partners deployed $89.7M of net new capital in Q3 2025, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was ProShares Ultra Gold: 537,372 shares worth $24.8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Verona Pharma, an estimated $56.9M trimmed.

  • Artia Global Partners's largest Q3 2025 buy was ProShares Ultra Gold: 537,372 shares worth $24.8M.
  • Artia Global Partners added most to Vertex Pharmaceuticals in Q3 2025, an estimated $21.2M increase.
  • Artia Global Partners's biggest Q3 2025 reduction was Verona Pharma, cutting an estimated $56.9M.
  • Artia Global Partners fully exited SpringWorks Therapeutics in Q3 2025, selling an estimated $3M.
  • Artia Global Partners's ten largest holdings make up 70% of its $631M portfolio in Q3 2025.
  • Artia Global Partners opened 19 new positions and closed 5 in Q3 2025.
  • Artia Global Partners's portfolio value rose 52% quarter-over-quarter to $631M.

Based on Artia Global Partners's 13F filing for Q3 2025, filed 14 Nov 2025.